Key Findings
Satri-cel has become the first regulator-approved CAR-T-cell therapy for a solid tumour, approved by China’s National Medical Products Administration in June 2026 for CLDN18.2-positive, HER2-negative advanced gastric cancer. In the randomised Phase II CT041-ST-01 trial, Satri-cel increased median progression-free survival from 1.77 to 3.25 months compared to physician’s-choice treatment in heavily pretreated gastric and gastro-oesophageal junction cancer.
Technical Details
To combat relapse caused by antigen escape, three architectural strategies for multi-antigen targeting are being developed:
- Pooled approaches: Administering two separate monospecific products (e.g., CD19- and CD22-directed cells).
- Bicistronic dual-CAR T cells: A single cell carrying two independent receptors (OR-gate), which provides uniform coverage but increases genetic payload.
- Tandem CARs: Fusing two binding domains into one receptor chain, though performance is sensitive to linker flexibility and steric hindrance.
Receptor evolution has progressed through four generations: first-generation (CD3ζ only), second-generation (adding CD28 or 4-1BB costimulation), third-generation (two costimulatory domains), and fourth-generation “armoured” CARs, which include inducible transgenes like IL-12 or IL-18 to remodel the tumour microenvironment.
Background & Context
While products like tisagenlecleucel and axicabtagene ciloleucel have treated blood cancers, solid tumours present harder challenges. Previous trials in glioblastoma (EGFRvIII) and lung tissue (HER2) highlighted issues such as rapid antigen loss, on-target off-tumour toxicity, and the presence of a dense desmoplastic stroma. The solid tumour microenvironment is further complicated by TGF-β, IL-10, and adenosine, which drive cell exhaustion via PD-1, TIM-3, and LAG-3 receptors.
Significance & Outlook
The approval of Satri-cel serves as a proof of principle for treating solid tumours, though challenges remain regarding antigen density and the frequency of grade 3 or worse adverse events. The future of the field depends on integrating receptor design with biomarker science, engineering, and health economics to reduce prohibitive costs and manufacturing bottlenecks.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
